Results of a recent Greek study show that high levels of the protein sclerostin in the blood are associated with advanced disease and poor bone formation in multiple myeloma patients.

In addition, the results indicate that Velcade may be effective in reducing sclerostin levels in myeloma patients.

“Our study has shown that sclerostin is increased in myeloma patients, and together with the [laboratory] data presented at the last ASH meeting, suggests that sclerostin inhibits the function of [bone-building cells] in myeloma,” said Dr. Evangelos Terpos of the Alexandra General Hospital in Athens, …